Entering text into the input field will update the search result below

Nabriva commences exclusive distribution of SIVEXTRO in the U.S.

  • Nabriva Therapeutics (NBRV +1.4%) announces that it has begun exclusive distribution of skin treatment SIVEXTRO (tedizolid phosphate) in the United States.
  • SIVEXTRO was approved by the U.S. FDA in 2014, and is indicated in adults and pediatric patients 12 years of age and older

Recommended For You

About NBRVF Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NBRVF--
Nabriva Therapeutics plc